Skip to main content

Lee Kevin's Form 4 filing

Bicycle Therapeutics PLC (BCYC) · filed Sep 3, 2021

Accession no.
0001209191-21-054787
Filed
Sep 3, 2021
Trade date
Sep 1-2, 2021
Filing delay
2 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 5 non-derivative transactions and 1 derivative transaction. Open-market sales total $1.21M. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Lee KevinCIK 0001776938Director, Officer (Chief Executive Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Sep 1, 2021Ordinary SharesMOption exerciseAcquired+22,890$14.00+$320,460267,170Direct
Sep 1, 2021Ordinary SharesSSaleDisposed−8,191$36.38F2−$297,988.58258,979Direct
Sep 1, 2021Ordinary SharesSSaleDisposed−17,098$37.52F3−$641,516.96241,881Direct
Sep 1, 2021Ordinary SharesSSaleDisposed−1,796$38.08F4−$68,391.68240,085Direct
Sep 2, 2021Ordinary SharesSSaleDisposed−5,000$40.00−$200,000235,085Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Sep 1, 2021Ordinary SharesMOption exerciseDisposed−22,890$0.00$0306,252Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.00 to $36.975 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4).

Referenced by the price of 1 transaction in Table I.

F3

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.00 to $37.99 inclusive.

Referenced by the price of 1 transaction in Table I.

F4

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.00 to $38.255 inclusive.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)